Like B16-F10, subcutaneously implanted B16-OVA-GFP tumors in C57BL/6J mice treated with combination anti-PD-1 and anti-PD-L1 led to controlled tumor growth and increased CD45+ immune cell infiltration (Figures 5B and 5C). The gene discussed is PDCD1; the disease is neoplasm.